KORU Medical Systems, Inc.

Equities

KRMD

US7599101026

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 01:18:32 2024-04-25 pm EDT			5-day change	1st Jan Change
2.18 ^USD	-0.91%		+5.34%	-11.61%

Mar. 13	Transcript : KORU Medical Systems, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	KORU Medical Systems, Inc. Enters into Loan and Security Agreement with HSBC Ventures USA Inc	CI

Repro Med Systems, Inc. Provides Revenue Guidance for the Fiscal Year 2022

March 02, 2022 at 04:01 pm EST

Repro Med Systems, Inc. provided revenue guidance for the fiscal year 2022. For fiscal year 2022, the Company expects revenue growth in the low to mid double digits, or $26.0 to $27.0 million on a full year basis.

Latest news about KORU Medical Systems, Inc.

Transcript : KORU Medical Systems, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
KORU Medical Systems, Inc. Enters into Loan and Security Agreement with HSBC Ventures USA Inc	Mar. 13	CI
KORU Medical Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
KORU Medical Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Reports Q4 Revenue $7.2M, vs. Street Est of $6.9M	Mar. 13	MT
KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024	Mar. 13	CI
KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic	Mar. 11	CI
KORU Medical Systems, Inc. Signs Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for Novel Subcutaneous Immunoglobulin	Mar. 06	CI
Transcript : KORU Medical Systems, Inc. - Analyst/Investor Day	Dec. 05
Transcript : KORU Medical Systems, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q3 Revenue $7M, vs. Street Est of $7.9M	Nov. 08	MT
KORU Medical Systems, Inc. Announces Development Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System	Nov. 08	CI
KORU Medical Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer	Nov. 08	CI
KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled Syringes	Nov. 07	CI
KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to its Board of Directors	23-10-04	CI
Lake Street Starts Repro Med Systems at Buy	23-09-07	MT
B. Riley Starts Repro Med Systems at Buy With $4.50 Price Target, Says Risk/Reward Becoming More Favorable	23-09-07	MT
Transcript : KORU Medical Systems, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Reports Q2 Revenue $6.9M, vs. Street Est of $7.2M	23-08-09	MT
KORU Medical Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
KORU Medical Systems, Inc. Updates Revenue Guidance for the Full Year 2023	23-08-09	CI
KORU Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023	23-08-02	CI
KORU Medical Systems, Inc. Announces Chief Financial Officer Changes	23-08-02	CI
KORU Medical Systems, Inc. Announces Novel Therapies Collaboration for Late-Stage Endocrinological Biologic	23-07-27	CI

Chart KORU Medical Systems, Inc.

Duration

Period

More charts

Company Profile

KORU Medical Systems, Inc. designs, manufactures, and markets proprietary portable and advanced medical devices primarily for the subcutaneous drug delivery market. It is focused on home and specialty infusion solutions. The Companyâs focus is primarily concentrated on its mechanical infusion products, the FREEDOM Infusion Systems, which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. The devices are used for infusions administered at home and in alternate care settings. Its infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patientâs subcutaneous tissues can tolerate and what the system delivers.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for KORU Medical Systems, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.2 USD

Average target price

3.375 USD

Spread / Average Target

+53.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
KORU MEDICAL SYSTEMS, INC.	-11.61%	102M
ABBOTT LABORATORIES	-3.10%	185B
MEDTRONIC PLC	-3.64%	107B
BECTON, DICKINSON AND COMPANY	-5.20%	67.55B
DEXCOM, INC.	+10.31%	54.6B
CENCORA, INC.	+17.27%	47.42B
HOYA CORPORATION	+3.86%	42.24B
WEST PHARMACEUTICAL SERVICES, INC.	+6.70%	28.24B
METTLER-TOLEDO INTERNATIONAL, INC.	+0.68%	26.42B
TERUMO CORPORATION	+12.40%	25.66B

Other Medical Equipment, Supplies & Distribution